Evidence map›Paper›PMID 19901946›Full record

ArticleThe Journal of investigative dermatology2009

Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells.

Rachael A Clark

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. The four types of Tregs in malignant lymphomas.Journal of hematology & oncology · 2011
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Rachael A ClarkHarvard Skin Disease Research Center and the Department of Dermatology, Brigham and Women's Hospital, EBRC Room 505A, 221 Longwood Avenue, Boston, Massachusetts 02115, USA. rclark1@partners.org
Brigham and Women's Hospital · US

Funding

Immune Evasion in Human Squamous Cell Carcinomas of the SkinR01AR056720 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2009 to 2013
$1.9M
Toll Receptor Ligand Therapy of Cutaneous T-Cell LymphomaR01CA122569 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROOK, ALAIN H · 2008 to 2011
$1.1M
T cell production from a skin derived thymus constructK08AI060890 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2006 to 2009
$540k
NCI NIH HHS 1R01CA122569NCI NIH HHS R01 CA122569NIAID NIH HHS 1K08AI060890NIAID NIH HHS K08 AI060890NIAMS NIH HHS 1R01AR056720NIAMS NIH HHS R01 AR056720
6 · The paper itself

Abstract

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas derived from T cells that home to and inhabit the skin. There are conflicting reports as to whether CTCLs represent a malignancy of regulatory T cells (Tregs), a T-cell subset that can suppress local immune reactions. In this issue, Heid et al. present convincing evidence that the malignant T cells in a subgroup of Sézary patients are FOXP3(+) regulatory T cells. Clonal malignant T cells showed increased expression of the Treg-associated transcription factor FOXP3 and demethylation of the FOXP3 gene locus, and T cells from at least some of these patients suppressed T-cell proliferation in vitro.

Indexed as

HumansImmune ToleranceSezary SyndromeSkin NeoplasmsT-Lymphocytes, Regulatory

Identifiers

PMID19901946
PMCPMC2921831
OpenAlexW2011211749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.